Management of Hyponatremia with Elevated BUN/Creatinine Ratio

Initial Assessment and Diagnosis

The American Heart Association suggests that an elevated BUN/creatinine ratio in the setting of hyponatremia indicates either hypovolemia requiring volume expansion or heart failure-related congestion with neurohormonal activation, and determining volume status is crucial to guide treatment strategies 1
The European Society of Cardiology indicates that hypovolemia is characterized by true volume depletion with prerenal azotemia requiring fluid resuscitation, while hypervolemia with congestion is associated with heart failure or cirrhosis and neurohormonal activation 1, 2
Key clinical parameters to assess include physical examination for jugular venous distension, peripheral edema, pulmonary congestion, or signs of dehydration, as recommended by the European Society of Cardiology 2

In patients with cirrhosis and sodium levels between 121-125 mEq/L, and elevated creatinine (>150 μmol/L or rising), the European Association for the Study of the Liver recommends stopping diuretics and giving volume expansion with colloid or saline 3, 4
For cirrhotic patients with severe hyponatremia (<120 mEq/L) and renal dysfunction, volume expansion takes priority over worsening ascites, as stated by the European Association for the Study of the Liver 3, 4
The American College of Cardiology suggests that in hypervolemic hyponatremia, the elevated BUN/creatinine ratio reflects neurohormonal activation with arginine vasopressin-mediated urea reabsorption, not true hypovolemia 1, 2

The European Society of Cardiology recommends that patients with hypervolemic hyponatremia should not restrict water if sodium levels are >126 mEq/L, and diuretics should be continued with monitoring of electrolytes 3, 4
For patients with sodium levels between 121-125 mEq/L and normal creatinine, the international consensus suggests continuing diuretics, but a cautious approach is to stop diuretics and observe, as recommended by the European Association for the Study of the Liver 3, 4
The American Heart Association indicates that vasopressin receptor antagonists, such as tolvaptan, can be used for hypervolemic and euvolemic hyponatremia, but should be initiated in a hospital setting with frequent sodium monitoring 3, 4

The European Society of Cardiology recommends monitoring serum sodium every 2-4 hours during active correction, then every 6-8 hours once stable, as well as daily monitoring of BUN, creatinine, and electrolytes 1
The American College of Cardiology suggests assessing volume status (weight, physical exam, intake/output) and neurologic status for signs of osmotic demyelination or worsening hyponatremia 2